Battle of the Biotech Unicorns: CureVac vs. Moderna
An interview never seen before. We brought together the founders and CEOs of the two…
November 6, 2017 - 4 minutes
mRNA: A New Technology Moving into the Mainstream
Messenger RNA (mRNA) technology is based on the idea that human cells can be used as on-demand factories to develop therapeutic proteins by giving them instructions in the form of mRNA. Although mRNA therapeutics and vaccines could be found in drug development pipelines before Covid-19 emerged, the pandemic suddenly moved the mRNA technology into the limelight.
Now, the world has seen mass vaccinations using mRNA-based vaccines developed by Moderna and Pfizer/BioNTech. But the mRNA technology holds promise for other indications as well, including cancer and rare diseases. Read on to learn how this new technology is moving into the mainstream with an influx of investments and new discoveries.
Show More
Editor's Picks for mRNA technology
- Could mRNA Vaccines Fulfill Their Potential Against Coronavirus?
- The COVID-19 pandemic has driven RNA therapeutics into the mainstream
- EMA Greenlights BioNTech and Pfizer mRNA Vaccine for Covid-19
- Next-Generation mRNA Vaccine Technology Unveiled in Series A Round
- Sanofi’s Translate Bio Buyout Shows Growing Hunger for mRNA Technology
European Biotech Industry Report 2021
This report discusses how the Covid-19 pandemic impacted Europe’s life science industry and covers recent market trends, investments, and collaborations.
Go to ReportLatest mRNA technology Articles
AstraZeneca and Moderna want to beat Novartis at Treating Heart Failure
AstraZeneca will work with Moderna Therapeutics to bring together to the market an mRNA version of Novartis' failed…
November 2, 2017 - 2 minutes
Eli Lilly Offers German Biotech up to €1.5Bn to Develop mRNA Cancer Vaccines
CureVac will be working with pharma giant Eli Lilly in the development of up to…
October 18, 2017 - 3 minutes
These Three Fields Are Proving Biotech is The Innovation Powerhouse in Healthcare
Biotech is the best source of innovation in R&D, making its companies the darlings of…
September 26, 2017 - 8 minutes
Belgian Biotech Gets €1M Grant to Boost its mRNA Cancer Immunotherapies
Flanders Innovation and Entrepreneurship has given eTheRNA a €1M grant to further improve its TriMix…
September 25, 2017 - 1 minute
RNA as a Therapy: Reviewing the Future Generation of Therapeutics
You’ve certainly heard about antibodies, peptides and even DNA as therapeutics, but what about RNA?…
September 19, 2017 - 9 minutes
AstraZeneca Teams Up with German Biotech to Develop mRNA Therapy
AstraZeneca and its R&D arm MedImmune have partnered with Munich-based Ethris to use its mRNA…
August 21, 2017 - 2 minutes
German Biotech Publishes First-in-Human Data on Rabies mRNA Vaccine
CureVac has published proof-of-concept data for an mRNA rabies vaccine that could open the door…
July 26, 2017 - 3 minutes
Results are in from the First Human Trial of an Universal Cancer Vaccine
BioNTech has published results from the first clinical trial for an mRNA-based individualized vaccine with…
July 5, 2017 - 4 minutes
Video: Is mRNA a True Game-Changer? Fireside Chat with Sean Marett, COO of BioNTech
Sean Marett took a red-eye from New York to speak at Refresh last month: here…
July 3, 2017 - 1 minute
Belgian Biotech Starts Phase Ib with an off-the-shelf mRNA Therapy for Melanoma
eTheRNA has started a Phase Ib trial in patients with melanoma to test a cancer immunotherapy…
June 30, 2017 - 2 minutes
BioNTech Publishes First Data on mRNA-Encoded Cancer Antibodies
BioNTech has reported a new technology that could overcome some of the most challenging issues…
June 12, 2017 - 3 minutes
